Nepafenac

• CAT Number: A001187
• CAS Number: 78281-72-8
• Molecular Formula: C15H14N2O2
• Molecular Weight: 254.28
• Purity: ≥95%
• Synonyms: AHR 9434, AL 6515
• Target: Anti-infection
• Solubility: >10mg/mL in DMSO
• Storage: 3 years -20C powder
• SMILES: O=C(N)CC1=CC=CC(C(C2=CC=CC=C2)=O)=C1N

Nepafenac(cas 78281-72-8) is a non-steroidal anti-inflammatory drug (NSAID), usually sold as a prescription eye drop. 


It is used to treat pain and inflammation associated with cataract surgery. The usual dose is 1 drop in each affected eye beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period. Its side effects may include decreased visual acuity, a feeling that something is in the eye, increased eye pressure or a sticky sensation, as well as other effects. 

Reference

1:Ophthalmic nepafenac use in the Netherlands and Denmark. Margulis AV, Houben E, Hallas J, Overbeek JA, Pottegård A, Torp-Pedersen T, Perez-Gutthann S, Arana A.Acta Ophthalmol. 2017 May 10. doi: 10.1111/aos.13468. [Epub ahead of print] PMID: 28493461
2:Effect of topical nepafenac in prevention of macular edema after cataract surgery in patients with non-proliferative diabetic retinopathy. Sarfraz MH, Haq RI, Mehboob MA.Pak J Med Sci. 2017 Jan-Feb;33(1):210-214. doi: 10.12669/pjms.331.11644. PMID: 28367202 Free PMC Article
3:Nepafenac 0.3% after Cataract Surgery in Patients with Diabetic Retinopathy: Results of 2 Randomized Phase 3 Studies. Singh RP, Lehmann R, Martel J, Jong K, Pollack A, Tsorbatzoglou A, Staurenghi G, Cervantes-Coste Cervantes G, Alpern L, Modi S, Svoboda L, Adewale A, Jaffe GJ.Ophthalmology. 2017 Mar 4. pii: S0161-6420(16)31411-7. doi: 10.1016/j.ophtha.2017.01.036. [Epub ahead of print] PMID: 28268098 Free Article
4:Comparison of the efficacy and patients/’ tolerability of Nepafenac and Ketorolac in the treatment of ocular inflammation following cataract surgery: A meta-analysis of randomized controlled trials. Zhao X, Xia S, Wang E, Chen Y.PLoS One. 2017 Mar 2;12(3):e0173254. doi: 10.1371/journal.pone.0173254. eCollection 2017. PMID: 28253334 Free PMC Article
5:Pseudophakic cystoid macular edema prevention and risk factors; prospective study with adjunctive once daily topical nepafenac 0.3% versus placebo. McCafferty S, Harris A, Kew C, Kassm T, Lane L, Levine J, Raven M.BMC Ophthalmol. 2017 Feb 20;17(1):16. doi: 10.1186/s12886-017-0405-7. PMID: 28219426 Free PMC Article
6:Effect of nepafenac on the foveal profile of glaucomatous patients undergoing phacoemulsification. Milla E, Stirbu O, Franco IJ, Hernández SJ, Rios J, Duch S.Int Ophthalmol. 2016 Oct 22. [Epub ahead of print] PMID: 27771823
7:Eyelid excoriation and erythema with nepafenac eye drop. Saurabh K, Roy R, Das D, Lobo A.Indian Dermatol Online J. 2016 Jul-Aug;7(4):324-5. doi: 10.4103/2229-5178.185478. No abstract available. PMID: 27559517 Free PMC Article
8:Comparison of the Tolerability of Diclofenac and Nepafenac. Achiron A, Karmona L, Mimouni M, Gershoni A, Dzhanov Y, Gur Z, Burgansky Z.J Ocul Pharmacol Ther. 2016 Nov;32(9):601-605. Epub 2016 Aug 11. PMID: 27513223
9:Prospective randomised clinical trial to evaluate the safety and efficacy of nepafenac 0.1% treatment for the prevention of macular oedema associated with cataract surgery in patients with diabetic retinopathy. Pollack A, Staurenghi G, Sager D, Mukesh B, Reiser H, Singh RP.Br J Ophthalmol. 2017 Apr;101(4):423-427. doi: 10.1136/bjophthalmol-2016-308617. Epub 2016 Jul 7. PMID: 27388251
10:Corneal Melting after Collagen Cross-Linking for Keratoconus in a Thin Cornea of a Diabetic Patient Treated with Topical Nepafenac: A Case Report with a Literature Review. Mohamed-Noriega K, Butrón-Valdez K, Vazquez-Galvan J, Mohamed-Noriega J, Cavazos-Adame H, Mohamed-Hamsho J.Case Rep Ophthalmol. 2016 Feb 26;7(1):119-24. doi: 10.1159/000444437. eCollection 2016 Jan-Apr. PMID: 27293413 Free PMC Article